1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient demographic/clinical data and lesion counts^{^a}
Sex Age (yr) Disease Duration (yr) Treatment Type Minimum WM Lesion Age (mo) Cortical Lesion WM Lesion Mixed Lesion
Patient 
    1 F 37 11 Copaxone^{^b} 12 2 6 1
    2 M 42 12 Copaxone 10 1 11 0
    3 F 42 3 Copaxone 8 0 2 0
    4 F 30 3 Tysabri^{^c} 9 5 23 1
    5 F 49 2 Rebif^{^d} 18 7 13 1
    6 M 32 6 Copaxone 10 3 30 4
    7 M 42 1 Copaxone 7 1 5 0
    8 F 33 1 Copaxone 10 0 4 0
    9 F 44 15 No Treatment 6 0 4 1
    10 F 31 1 No Treatment 3 0 12 0
    11 F 41 16 Tysabri 4 2 15 1
    12 F 58 25 Copaxone 6 6 7 0
    13 M 37 8 Copaxone 13 0 15 0
    14 M 48 6 Copaxone 5 0 0 0
Mean 40.4 ± 7.9 7.9 ± 7.2 8.6 ± 4.0 1.9 ± 2.3 10.5 ± 8.4 0.64 ± 1.1
Total 27 147 9
↵a Patients 9 and 10 were not on any disease-modifying treatment at the time of their 7T scans. Patient 9 was on Tysabri, but it was stopped 6 months prior to her 7T scan. All patients had relapsing-remitting MS except patient 11, who was in a transitional stage between relapsing-remitting MS and secondary-progressive MS but was still being treated for relapsing-remitting MS. Patient 14 had lesions that all regressed before the 7T scan.
↵b Glatiramer acetate injection.
↵c Natalizumab.
↵d Interferon β-1a.